Imaging Cardiac Amyloidosis: A Pilot Study Using F-18 Florbetapir Positron Emission Tomography
Status:
Unknown status
Trial end date:
2020-06-01
Target enrollment:
Participant gender:
Summary
The primary aim of this pilot study is to determine whether amyloid deposits in the heart can
be measured non-invasively by F-18 florbetapir (Trade Name: Amyvid) positron emission
tomography (PET) in 30 individuals with documented cardiac amyloidosis. We will also enroll
15 individuals without cardiac amyloidosis to undergo the F-18 florbetapir imaging as a
control group.
The primary hypothesis of this study is that a specific amyloid binding radiotracer will bind
to the myocardial amyloid deposits and help quantify cardiac amyloid burden.
A secondary aim of this study is to determine reproducibility of F-18 florbetapir imaging of
the myocardium.